Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder.


Journal Article

Bipolar disorder is a complex neuropsychiatric disorder that is characterized by intermittent episodes of mania and depression; without treatment, 15% of patients commit suicide. Hence, it has been ranked by the World Health Organization as a top disorder of morbidity and lost productivity. Previous neuropathological studies have revealed a series of alterations in the brains of patients with bipolar disorder or animal models, such as reduced glial cell number in the prefrontal cortex of patients, upregulated activities of the protein kinase A and C pathways and changes in neurotransmission. However, the roles and causation of these changes in bipolar disorder have been too complex to exactly determine the pathology of the disease. Furthermore, although some patients show remarkable improvement with lithium treatment for yet unknown reasons, others are refractory to lithium treatment. Therefore, developing an accurate and powerful biological model for bipolar disorder has been a challenge. The introduction of induced pluripotent stem-cell (iPSC) technology has provided a new approach. Here we have developed an iPSC model for human bipolar disorder and investigated the cellular phenotypes of hippocampal dentate gyrus-like neurons derived from iPSCs of patients with bipolar disorder. Guided by RNA sequencing expression profiling, we have detected mitochondrial abnormalities in young neurons from patients with bipolar disorder by using mitochondrial assays; in addition, using both patch-clamp recording and somatic Ca(2+) imaging, we have observed hyperactive action-potential firing. This hyperexcitability phenotype of young neurons in bipolar disorder was selectively reversed by lithium treatment only in neurons derived from patients who also responded to lithium treatment. Therefore, hyperexcitability is one early endophenotype of bipolar disorder, and our model of iPSCs in this disease might be useful in developing new therapies and drugs aimed at its clinical treatment.

Full Text

Cited Authors

  • Mertens, J; Wang, Q-W; Kim, Y; Yu, DX; Pham, S; Yang, B; Zheng, Y; Diffenderfer, KE; Zhang, J; Soltani, S; Eames, T; Schafer, ST; Boyer, L; Marchetto, MC; Nurnberger, JI; Calabrese, JR; Ødegaard, KJ; McCarthy, MJ; Zandi, PP; Alda, M; Nievergelt, CM; Pharmacogenomics of Bipolar Disorder Study, ; Mi, S; Brennand, KJ; Kelsoe, JR; Gage, FH; Yao, J

Published Date

  • November 2015

Published In

Volume / Issue

  • 527 / 7576

Start / End Page

  • 95 - 99

PubMed ID

  • 26524527

Pubmed Central ID

  • 26524527

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

International Standard Serial Number (ISSN)

  • 0028-0836

Digital Object Identifier (DOI)

  • 10.1038/nature15526


  • eng